Medtech Execs On The Move, December 2015
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
You may also be interested in...
Perrigo says 2024 results will be slowed by investment in companywide investment and efficiency project including staff reductions. After Opill’s expected launch by late March, sales will be dilutive to earnings for the first year partly due to investments in the brand, primarily at retailers and online in Q2.
Janux reported early clinical trial data for its lead asset JANX007 that may show differentiated efficacy in the crowded PSMA space and for an EGFR agent with lung and kidney tumor shrinkage.
Incyte’s Jakafi-dominated portfolio gained Opzelura as a second source of significant revenue in 2021. While further diversification has been limited, new and existing R&D assets may deliver upside in 2024.